VoiceRPA Is Coming To Healthcare With Infinitus

VoiceRPA Is Coming To Healthcare With Infinitus

Infinitus is a voice robotic process automation (VoiceRPA) company that is targeting the complexity and cost in U.S. healthcare. Another player in the healthcare robotic process automation (RPA) arena just completed a large capital raise. These RPA companies are bringing enterprise cloud/SaaS dynamism towards a much-needed re-platforming of the ailing and inefficient U.S. healthcare industry. … Read more

Strand Therapeutics Aims For Genetically-Programed RNA

Strand Therapeutics Aims For Genetically-Programed RNA

Strand Therapeutics, a private company based in Massachusetts, is building a platform based on technology developed by biological engineers at MIT including scientific co-founders, Professor Ron Weiss, Ph.D., a pioneer of the field of synthetic biology, and Professor Darrell J. Irvine, Ph.D., a leading researcher of materials for immune-engineering. The co-founders sought to apply synthetic … Read more

DARPA Dive: Seeking Self-Healing, Hybrid Biological Structures

DARPA Dive: Seeking Self-Healing, Hybrid Biological Structures

The Defense Advanced Research Projects Agency (DARPA), established in 1958, is an agency within the Department of Defense (DOD) responsible for catalyzing the development of technologies that maintain and advance the capabilities and technical superiority of the U.S. military. In short, it’s the way the U.S. military tries to prevent technical surprise. DARPA is seeking … Read more

What Is T-cell Transfer Therapy?

What Is T-cell Transfer Therapy?

T-cell transfer therapy is a type of immunotherapy that makes your own immune cells better able to attack cancer. There are two main types of T-cell transfer therapy: tumor-infiltrating lymphocytes (or TIL) therapy and chimeric antigen receptor T-cell (CAR T-cell) therapy. Both involve collecting your own immune cells, growing large numbers of these cells in … Read more

What Are Cell-Free Systems?

What Are Cell-Free Systems?

Living systems are not only complex, they are relentless in their demands to be kept alive, with all the attendant limitations and challenges for experimentation and measurement. So-called “cell-free systems” inhabit the space between chemistry and biology proper, obviating some of the requirements of living, cell-based systems and enabling biochemical processes and experimental interventions toxic, … Read more

FDA: Artificial Intelligence/Machine Learning (AI/ML)-Based Software As A Medical Device (SaMD)

FDA: Artificial Intelligence/Machine Learning (AI/ML)-Based Software As A Medical Device (SaMD)

Human biology and new, more advanced computing is creating new territory for therapies that were not capable even five years ago. Artificial intelligence (AI) and machine learning (ML) technologies have the potential to transform health care by deriving new and important insights from the vast amount of health data. Medical device manufacturers are using these … Read more

Pacific Biosciences And Invitae Agree To Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

Pacific Biosciences And Invitae Agree To Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

Pacific Biosciences today announced a multi-year collaboration with Invitae Corporation to begin development of a production-scale high-throughput sequencing platform. Identifying the many underlying genetic influences on human health is emerging as a tool for evaluating overall clinical care and prognosis. Whole genome sequencing offers the most comprehensive view of medically relevant genetic variations. PacBio cites … Read more

Synthetic Biologics Targets The Microbiome For GI Therapies

Synthetic Biologics Targets The Microbiome For GI Therapies

Synthetic Biologics, Inc is clinical-stage company leveraging the microbiome to develop therapeutics designed to treat gastrointestinal (GI) diseases. The Company’s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), … Read more